Charles River/$CRL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Charles River
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Ticker
$CRL
Sector
Primary listing
NYSE
Employees
19,400
Headquarters
Website
Charles River Metrics
BasicAdvanced
$7.5B
-
-$1.37
1.48
-
Price and volume
Market cap
$7.5B
Beta
1.48
52-week high
$217.00
52-week low
$91.86
Average daily volume
917K
Financial strength
Current ratio
1.36
Quick ratio
0.88
Long term debt to equity
81.952
Total debt to equity
82.039
Interest coverage (TTM)
4.60%
Profitability
EBITDA (TTM)
1,001.248
Gross margin (TTM)
35.03%
Net profit margin (TTM)
-1.66%
Operating margin (TTM)
14.41%
Effective tax rate (TTM)
-257.39%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
4.68%
Return on equity (TTM)
-1.81%
Valuation
Price to revenue (TTM)
1.92
Price to book
2.24
Price to tangible book (TTM)
-40.58
Price to free cash flow (TTM)
13.37
Free cash flow yield (TTM)
7.48%
Free cash flow per share (TTM)
11.435
Growth
Revenue change (TTM)
-1.21%
Earnings per share change (TTM)
-116.46%
3-year revenue growth (CAGR)
2.99%
10-year revenue growth (CAGR)
11.83%
3-year earnings per share growth (CAGR)
-45.74%
10-year earnings per share growth (CAGR)
-7.30%
What the Analysts think about Charles River
Analyst ratings (Buy, Hold, Sell) for Charles River stock.
Bulls say / Bears say
Charles River generates around $200 million in annual revenue from its New Approach Methodologies portfolio—AI-powered and human-cell-based testing—positioning it to benefit as the FDA advances efforts to cut animal testing and help clients lower costs (Reuters).
On May 7, 2025, CRL shares jumped 15%, their biggest single-day rise in over 13 years, after the company posted better-than-expected Q1 results, raised its full-year outlook, and launched a strategic review with Elliott Management, showing strong investor belief in its turnaround strategy (Barron's).
In July 2025, the U.S. Department of Justice ended both grand jury and civil probes into CRL’s non-human primate supply chain, lifting a major regulatory burden from its DSA business (SEC Filing).
CRL’s organic revenue dropped 0.5% year-over-year in Q2 2025, revealing ongoing demand weakness in its core Discovery and Safety Assessment segment (SEC Filing).
GAAP operating margin fell to 9.7% in Q2 2025, compared with 14.8% a year earlier, due to accelerated amortization of CDMO client relationships, restructuring charges, and higher outside legal and advisory expenses (SEC Filing).
The company’s revised 2025 guidance projects reported revenue down 0.5–2.5%, pointing to ongoing revenue shrinkage as biopharma R&D spending remains muted (SEC Filing).
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
Charles River Financial Performance
Revenues and expenses
Charles River Earnings Performance
Company profitability
Charles River News
AllArticlesVideos
Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing
Benzinga1 month ago
Creightons shares fall 10% as cautious outlook tempers improved results
Proactive Investors2 months ago
Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Charles River stock?
Charles River (CRL) has a market cap of $7.5B as of September 13, 2025.
What is the P/E ratio for Charles River stock?
The price to earnings (P/E) ratio for Charles River (CRL) stock is 0 as of September 13, 2025.
Does Charles River stock pay dividends?
No, Charles River (CRL) stock does not pay dividends to its shareholders as of September 13, 2025.
When is the next Charles River dividend payment date?
Charles River (CRL) stock does not pay dividends to its shareholders.
What is the beta indicator for Charles River?
Charles River (CRL) has a beta rating of 1.48. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.